A single-center, retrospective study assessing the efficacy and safety of nab-paclitaxel plus S1 combined with sintilimab in patients with metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 08 Apr 2022
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Mar 2022 Results published in the Langenbecks Archives of Surgery
- 09 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress